Pharmacologie des dérivés du platine: différences entre les trois composés et les facteurs de variabilité entre patients = Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variabilityCHATELUT, Etienne.Bulletin du cancer. 2011, Vol 98, Num 11, pp 1253-1261, issn 0007-4551, 9 p.Article

Population approaches in paediatricsCHATELUT, Etienne.Fundamental & clinical pharmacology. 2008, Vol 22, Num 6, pp 575-578, issn 0767-3981, 4 p.Conference Paper

Pharmacocinétique des médicaments anticancéreux et insuffisances fonctionnelles organiques = Pharmacokinetics and impaired organic functionsCHATELUT, Etienne.Bulletin du cancer. 2011, Vol 98, Num 11, pp 1347-1354, issn 0007-4551, 8 p.Article

Individualisation des doses en oncoloqie : médicaments anticancéreux (2e partie) = Individual dosing in oncologyTHOMAS, Fabienne; CHATELUT, Etienne.La Lettre du pharmacologue (Boulogne). 2008, Vol 22, Num 3, pp 92-97, issn 0984-452X, 6 p.Article

Pourquoi individualiser les doses de médicaments anticancéreux : de la surface corporelle à la physiologie = Anticancer drug dose individualisation : from body surface area to physiologyPETAIN, Aurélie; CHATELUT, Etienne.Bulletin du cancer. 2008, Vol 95, Num 10, pp 895-901, issn 0007-4551, 7 p.Article

Etude pharmacocinétique clinique de la diffusion de médicaments anticancéreux à travers les membranes physiologiques: application à l'administration intrapéritonéale et à la diffusion dans le liquide céphalo-rachidien = Clinical pharmacokinetic study of diffusion of anticancerous drugs through physiologic membranes: application to intraperitoneal administration and diffusion through the blood-brain barrierChatelut, Etienne; Houin, G.1991, 155 p.Thesis

Determination of Plasma Unbound Fraction of Voriconazole in Patients Treated With a Prophylactic or a Curative TreatmentFLORENT, Aurélie; GANDIA, Peggy; SERAISSO, Patrick et al.Therapeutic drug monitoring. 2014, Vol 36, Num 6, pp 752-758, issn 0163-4356, 7 p.Article

Niveau de preuve du suivi thérapeutique pharmacologique du cisplatine = Level of Evidence for Therapeutic Drug Monitoring of CisplatinHULIN, Anne; ROYER, Bernard; CHATELUT, Etienne et al.Thérapie (Paris). 2010, Vol 65, Num 3, pp 151-155, issn 0040-5957, 5 p.Article

Quantification of topotecan by liquid chromatography―mass spectrometry (LC―MS). Application to intestinal transport using rat everted gut sacsARELLANO, Cécile; GANDIA, Peggy; BETTUING, Laure et al.Journal of chromatography. B. 2010, Vol 878, Num 7-8, pp 645-652, issn 1570-0232, 8 p.Article

Should therapeutic drug monitoring of the unbound fraction of imatinib and its main active metabolite N-desmethyl-imatinib be developed?GANDIA, Peggy; ARELLANO, Cécile; LAFONT, Thierry et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 2, pp 531-536, issn 0344-5704, 6 p.Article

International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiencyLICHTMAN, Stuart M; WILDIERS, Hans; LAUNAY-VACHER, Vincent et al.European journal of cancer (1990). 2007, Vol 43, Num 1, pp 14-34, issn 0959-8049, 21 p.Article

Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification : Comparison across anticancer drugsKLOFT, Charlotte; WALLIN, Johan; HENNINGSSON, Anja et al.Clinical cancer research. 2006, Vol 12, Num 18, pp 5481-5490, issn 1078-0432, 10 p.Article

Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft : Pharmacokinetic and pharmacodynamic evaluationGUICHARD, Sylvie; MONTAZERI, Ashraf; CHATELUT, Etienne et al.Clinical cancer research. 2001, Vol 7, Num 10, pp 3222-3228, issn 1078-0432Article

Model-Based Approach to Describe G-CSF Effects in Carboplatin-Treated Cancer PatientsPASTOR, Mélanie L; LAFFONT, Céline M; GLADIEFF, Laurence et al.Pharmaceutical research. 2013, Vol 30, Num 11, pp 2795-2807, issn 0724-8741, 13 p.Article

Phase-i study of a new schedule based on increasing days of topotecan administration associated with dose individualisationDELORD, Jean-Pierre; LEGER, Frédéric; CANAL, Pierre et al.Cancer chemotherapy and pharmacology. 2006, Vol 58, Num 2, pp 189-194, issn 0344-5704, 6 p.Article

Ribavirin pharmacokinetics in renal and liver transplant patients: Evidence that it depends on renal functionKAMAR, Nassim; CHATELUT, Etienne; MANOLIS, Efthymios et al.American journal of kidney diseases. 2004, Vol 43, Num 1, pp 140-146, issn 0272-6386, 7 p.Article

Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patientsDU RIEU, Quentin Chalret; FOULIARD, Sylvain; WHITE-KONING, Mélanie et al.Investigational new drugs. 2014, Vol 32, Num 5, pp 985-994, issn 0167-6997, 10 p.Article

A Universal Formula Based on Cystatin C to Perform Individual Dosing of Carboplatin in Normal Weight, Underweight, and Obese PatientsSCHMITT, Antonin; GLADIEFF, Laurence; LE GUELLEC, Chantal et al.Clinical cancer research (Print). 2009, Vol 15, Num 10, pp 3633-3639, issn 1078-0432, 7 p.Article

A Phase I Dose-Escalating and Pharmacokinetic Study of Docetaxel and Vinorelbine as First-Line Chemotherapy for Metastatic Breast CancerDELORD, Jean Pierre; DALENC, Florence; PINGUET, Frédéric et al.Oncology. 2007, Vol 72, Num 5-6, pp 322-325, issn 0030-2414, 4 p.Article

International Society of Geriatric Oncology chemotherapy taskforce: Evaluation of chemotherapy in older patients: An analysis of the medical literatureLICHTMAN, Stuart M; WILDIERS, Hans; CHATELUT, Etienne et al.Journal of clinical oncology. 2007, Vol 25, Num 14, pp 1832-1843, issn 0732-183X, 12 p.Article

Mechanism-based models for topotecan-induced neutropeniaLEGER, Frédéric; LOOS, Walter J; BUGAT, Roland et al.Clinical pharmacology and therapeutics. 2004, Vol 76, Num 6, pp 567-578, issn 0009-9236, 12 p.Article

Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil- based therapy together with cetuximab-irinotecanETIENNE-GRIMALDI, Marie-Christine; BENNOUNA, Jaafar; JACOB, Jacques-Henri et al.British journal of clinical pharmacology. 2012, Vol 73, Num 5, pp 776-785, issn 0306-5251, 10 p.Article

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinomaTHOMAS, Fabienne; ROCHAIX, Philippe; WHITE-KONING, Melanie et al.European journal of cancer (1990). 2009, Vol 45, Num 13, pp 2316-2323, issn 0959-8049, 8 p.Article

Serum Cystatin C is a better marker of topotecan clearance than serum creatinineHOPPE, Antje; SERONIE-VIVIEN, Sophie; THOMAS, Fabienne et al.Clinical cancer research. 2005, Vol 11, Num 8, pp 3038-3044, issn 1078-0432, 7 p.Article

Cystatin C as a new covariate to predict renal elimination of drugs : Application to carboplatinTHOMAS, Fabienne; SERONIE-VIVIEN, Sophie; GLADIEFF, Laurence et al.Clinical pharmacokinetics. 2005, Vol 44, Num 12, pp 1305-1316, issn 0312-5963, 12 p.Article